{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T01:03:59Z","timestamp":1795223039615,"version":"4.10.3"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Locally advanced oral squamous cell carcinoma (LAOSCC) is associated with a high rate of recurrence and poor survival. Given the recent successes of neoadjuvant immunochemotherapy (NAICT) in solid tumors, it is promising to use this treatment modality to achieve a better pathological response and improve the survival of LAOSCC, and clinical evidence is needed to assess its safety and efficacy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>A prospective trial of NAICT with toripalimab (PD-1 inhibitor) and albumin paclitaxel\/cisplatin (TTP) was conducted in patients with clinical stage III and IVA OSCC. Intravenous albumin paclitaxel (260\u00a0mg\/m<jats:sup>2<\/jats:sup>), cisplatin (75\u00a0mg\/m<jats:sup>2<\/jats:sup>), and toripalimab (240\u00a0mg) were given in sequence on day 1 of each 21 day cycle for two cycles, followed by radical surgery and risk-adapted adjuvant (chemo)radiotherapy. The primary endpoints were safety and major pathological response (MPR). Targeted next generation sequencing and multiplex immunofluorescence were performed to assess clinical molecular characteristics and the tumor immune microenvironment in the pre-NAICT and post-NAICT tumor samples.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Twenty patients were enrolled. NAICT was well-tolerated with a low incidence of grades 3\u20134 adverse events in three patients. The completion rates of NAICT and subsequent R0 resection were 100%. The MPR rate was 60%, including a 30% pathological complete response. MPR was achieved in all four patients with a combined positive score of PD-L1&gt;10. The density of tertiary lymphatic structure in post-NAICT tumor samples predicted the pathological response to NAICT. During the median 23-month follow-up, the disease-free survival was 90%, and the overall survival was 95%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>NAICT with the TTP protocol in LAOSCC is feasible and well tolerated, with a promising MPR and no obstruction on subsequent surgery. This trial is supportive of further randomized trials using NAICT in LAOSCC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/js9.0000000000000489","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T06:00:17Z","timestamp":1686204017000},"page":"2220-2227","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":82,"title":["Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial)"],"prefix":"10.1097","volume":"109","author":[{"given":"Yingying","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Oral and Maxillofacial-Head and Neck Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Oral Pathology, Ninth People\u2019s Hospital, College of Stomatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial-Head and Neck Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongwang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial-Head and Neck Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjun","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjin","family":"Dou","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial-Head and Neck Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Tang","sequence":"additional","affiliation":[{"name":"Huangpu Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics in Clinical Research Unit, Ninth People\u2019s Hospital, Shanghai Jiao Tong University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongchao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial-Head and Neck Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial-Head and Neck Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial-Head and Neck Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial-Head and Neck Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oral Pathology, Ninth People\u2019s Hospital, College of Stomatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guopei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial-Head and Neck Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Medical Department, 3D Medicines Inc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Chen","sequence":"additional","affiliation":[{"name":"The Medical Department, 3D Medicines Inc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial-Head and Neck Oncology"},{"name":"Huangpu Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5022-1731","authenticated-orcid":false,"given":"Wutong","family":"Ju","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial-Head and Neck Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laiping","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial-Head and Neck Oncology"},{"name":"Huangpu Branch"},{"name":"National Center for Stomatology"},{"name":"National Clinical Research Center for Oral Diseases"},{"name":"Shanghai Key Laboratory of Stomatology, Shanghai, People\u2019s Republic China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8]]},"reference":[{"key":"R1-20250830","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1056\/NEJMra1715715","article-title":"Head and neck cancer","volume":"382","author":"Chow","year":"2020","journal-title":"N Engl J Med"},{"key":"R2-20250830","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.oraloncology.2018.10.013","article-title":"Oral cancers: current status","volume":"87","author":"D\u2019Cruz","year":"2018","journal-title":"Oral Oncol"},{"key":"R3-20250830","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1634\/theoncologist.2009-0289","article-title":"Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis","volume":"15","author":"Pulte","year":"2010","journal-title":"Oncologist"},{"key":"R4-20250830","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11912-020-00944-5","article-title":"The role of neoadjuvant therapy in melanoma","volume":"22","author":"Kelly","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"R5-20250830","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"key":"R6-20250830","doi-asserted-by":"crossref","first-page":"e1000267","DOI":"10.1371\/journal.pmed.1000267","article-title":"Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages","volume":"7","author":"Gillen","year":"2010","journal-title":"PLoS Med"},{"key":"R7-20250830","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1016\/S1470-2045(21)00383-1","article-title":"Revisiting neoadjuvant therapy in non-small-cell lung cancer","volume":"22","author":"Saw","year":"2021","journal-title":"Lancet Oncol"},{"key":"R8-20250830","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol"},{"key":"R9-20250830","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"key":"R10-20250830","doi-asserted-by":"crossref","first-page":"497","DOI":"10.4048\/jbc.2019.22.e49","article-title":"Predictive and prognostic roles of pathological indicators for patients with breast cancer on neoadjuvant chemotherapy","volume":"22","author":"Li","year":"2019","journal-title":"J Breast Cancer"},{"key":"R11-20250830","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cac2.12136","article-title":"Phase III trial of docetaxel cisplatin 5-fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome","volume":"41","author":"Ju","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"R12-20250830","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s40425-019-0662-5","article-title":"The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)","volume":"7","author":"Cohen","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R13-20250830","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"R14-20250830","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1158\/1078-0432.CCR-18-3944","article-title":"Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by prior cetuximab use","volume":"25","author":"Ferris","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R15-20250830","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/jamaoncol.2020.2955","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial","volume":"6","author":"Schoenfeld","year":"2020","journal-title":"JAMA Oncol"},{"key":"R16-20250830","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jamaoto.2021.2191","article-title":"Neoadjuvant PD-1\/PD-L1 inhibitors for resectable head and neck cancer: a systematic review and meta-analysis","volume":"147","author":"Masarwy","year":"2021","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"R17-20250830","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-20-1695","article-title":"Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial","volume":"26","author":"Uppaluri","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R18-20250830","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s42003-020-0811-x","article-title":"Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens","volume":"3","author":"Grimaldi","year":"2020","journal-title":"Commun Biol"},{"key":"R19-20250830","doi-asserted-by":"crossref","first-page":"772450","DOI":"10.3389\/fimmu.2021.772450","article-title":"The sequence of chemotherapy and toripalimab might influence the efficacy of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell cancer-a phase II study","volume":"12","author":"Xing","year":"2021","journal-title":"Front Immunol"},{"key":"R20-20250830","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11864-021-00885-6","article-title":"Neoadjuvant chemoimmunotherapy in patients with resectable non-small cell lung cancer","volume":"22","author":"Gutierrez-Sainz","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"R21-20250830","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"R22-20250830","doi-asserted-by":"crossref","first-page":"106165","DOI":"10.1016\/j.ijsu.2021.106165","article-title":"STROCSS 2021: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery","volume":"96","author":"Mathew","year":"2021","journal-title":"Int J Surg"},{"key":"R23-20250830","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1200\/JCO.2012.43.8820","article-title":"Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma","volume":"31","author":"Zhong","year":"2013","journal-title":"J Clin Oncol"},{"key":"R24-20250830","doi-asserted-by":"crossref","first-page":"5378","DOI":"10.1038\/s41467-022-33080-8","article-title":"A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma","volume":"13","author":"Ju","year":"2022","journal-title":"Nat Commun"},{"key":"R25-20250830","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.ijrobp.2019.03.012","article-title":"Is multifocal regression a risk factor for ipsilateral breast tumor recurrence in the modern era after neoadjuvant chemotherapy and breast conservation therapy?","volume":"104","author":"Ling","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R26-20250830","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nrclinonc.2016.195","article-title":"RECIST - learning from the past to build the future","volume":"14","author":"Litiere","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"R27-20250830","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"R28-20250830","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann Surg"},{"key":"R29-20250830","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.2003.06.146","article-title":"Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial","volume":"21","author":"Licitra","year":"2003","journal-title":"J Clin Oncol"},{"key":"R30-20250830","doi-asserted-by":"crossref","first-page":"e005160","DOI":"10.1136\/jitc-2022-005160","article-title":"Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis","volume":"10","author":"Zhai","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R31-20250830","doi-asserted-by":"crossref","first-page":"566315","DOI":"10.3389\/fonc.2020.566315","article-title":"Discordant responses between primary head and neck tumors and nodal metastases treated with neoadjuvant nivolumab: correlation of radiographic and pathologic treatment effect","volume":"10","author":"Merlino","year":"2020","journal-title":"Front Oncol"},{"key":"R32-20250830","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1200\/JCO.2004.09.062","article-title":"Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience","volume":"22","author":"Chen","year":"2004","journal-title":"J Clin Oncol"},{"key":"R33-20250830","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","article-title":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","volume":"2","author":"Vanhersecke","year":"2021","journal-title":"Nat Cancer"},{"key":"R34-20250830","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Sautes-Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"R35-20250830","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"R36-20250830","doi-asserted-by":"crossref","first-page":"100336","DOI":"10.1016\/j.esmoop.2021.100336","article-title":"Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers","volume":"7","author":"Palmeri","year":"2022","journal-title":"ESMO Open"},{"key":"R37-20250830","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.3390\/biomedicines10102498","article-title":"How risk factors affect head and neck squamous cell carcinoma (HNSCC) tumor immune microenvironment (TIME): their influence on immune escape mechanisms and immunotherapy strategy","volume":"10","author":"Galizia","year":"2022","journal-title":"Biomedicines"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000000489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T18:01:59Z","timestamp":1756576919000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000000489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":37,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000000489","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]},"assertion":[{"value":"2023-03-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}